Personalis Secures Medicare Coverage for Lung Cancer, Boosts Clinical Revenue 258% YoY
Event summary
- Personalis secured Medicare coverage for lung cancer surveillance, its second major coverage decision in six months.
- Clinical revenue surged 258% year-over-year to $1.4 million, with 7,815 clinical tests delivered in Q1 2026.
- Company reaffirmed full-year 2026 guidance, targeting $78.0–$80.0 million in total revenue and five-fold clinical revenue growth.
- Cash position stood at $233.2 million, including $21.0 million from ATM sales at $10.00 per share.
- NeXT Personal® test showcased strong data in breast cancer and colorectal cancer studies, demonstrating high predictive value.
The big picture
Personalis' Q1 2026 results underscore its strategic shift toward precision oncology, with Medicare coverage expansions and clinical data validating its NeXT Personal test. The company's focus on growing its MRD offering positions it to capitalize on the increasing demand for ultrasensitive cancer detection and monitoring. However, sustaining rapid clinical volume growth while managing gross margins and cash burn will be critical to its long-term success.
What we're watching
- Reimbursement Expansion
- Whether Personalis can secure Medicare coverage in additional oncology indications beyond breast and lung cancer.
- Clinical Adoption
- The pace at which NeXT Personal test volume scales to meet the projected 171% year-over-year growth at the midpoint.
- Competitive Positioning
- How Personalis differentiates its ultrasensitive MRD technology in a competitive precision oncology market.
Related topics